Download PDF
Semin Respir Crit Care Med
DOI: 10.1055/a-2803-3367
Narrative Review

The Impact of Acute Exacerbations of COPD on Patient Outcomes

Authors

  • Alberto Fantin

    1   Department of Pulmonology, Santa Maria della Misericordia University Hospital, Udine, Italy
    2   Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

  • Nadia Castaldo

    1   Department of Pulmonology, Santa Maria della Misericordia University Hospital, Udine, Italy

  • Giulia Sartori

    2   Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

  • Claudia Di Chiara

    2   Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

  • Giuseppe Morana

    1   Department of Pulmonology, Santa Maria della Misericordia University Hospital, Udine, Italy

  • Vincenzo Patruno

    1   Department of Pulmonology, Santa Maria della Misericordia University Hospital, Udine, Italy

  • Ernesto Crisafulli

    2   Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
Further Information
   Permissions and Reprints

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (ECOPD) represent major inflection points in the natural history of the disease, driving accelerated functional decline, reduced autonomy, and increased cardiovascular and mortality risk. This narrative review synthesizes current evidence on the multidimensional impact of ECOPD on patient outcomes, spanning respiratory physiology, muscle function, exercise capacity, inflammation, cardiovascular vulnerability, survival, and performance status. Across physiological domains, ECOPD induces sustained functional impairments that may take weeks to months to normalize. Muscular and functional consequences are similarly profound: Skeletal and diaphragmatic muscle dysfunction, reduced mobility, and long-lasting decrements in exercise tolerance contribute to prolonged disability and reduced quality of life. Systemic and airway inflammation often persists long after the acute phase, promoting recurrent exacerbations, progressive lung injury, and cardiometabolic complications. Cardiovascular instability is a defining feature of the post-ECOPD period, with markedly elevated short- and medium-term risks of myocardial infarction, stroke, arrhythmias, and acute heart failure. Mortality remains substantial post-ECOPD, and recurrent readmissions reflect ongoing physiological fragility. Autonomy, performance status, and health-related quality of life frequently remain impaired months after discharge, emphasizing the long-term functional burden of ECOPD. ECOPD recovery is therefore a subacute, high-risk phase of multisystem instability that requires integrated respiratory, cardiovascular, functional, and rehabilitative strategies. Future directions should prioritize personalized post-ECOPD care, guided by treatable traits, performance-based assessments, biomarkers, and digital monitoring. The development of ECOPD-specific functional endpoints and patient-centered outcomes represents a critical unmet need to advance research and improve long-term prognosis.

Keywords

COPD - exacerbation - outcome - dyspnea - quality of life - cardiovascular

Contributors' Statement

A.F.: Conceptualization, project administration, resources, supervision, validation, visualization, writing–original draft, writing–review and editing. N.C.: Conceptualization, supervision, writing–original draft, writing–review and editing. G.S.: Writing–original draft, writing–review and editing. C.D.C.: Writing–original draft, writing–review and editing. G.M.: Writing–original draft, writing–review and editing. V.P.: Writing–original draft, writing–review and editing. E.C.: Resources, supervision, validation, visualization, writing–original draft, writing–review and editing.




Publication History

Received: 11 December 2025

Accepted: 02 February 2026

Article published online:
24 February 2026

© 2026. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Adeloye D, Chua S, Lee C. et al; Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015; 5 (02) 020415
    Search in Google Scholar
  • 2 Boers E, Barrett M, Su JG. et al. Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open 2023; 6 (12) e2346598
    Search in Google Scholar
  • 3 GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403 (10440): 2100-2132
    Search in Google Scholar
  • 4 Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: Severe exacerbations and mortality. Thorax 2012; 67 (11) 957-963
    Search in Google Scholar
  • 5 Ko FW, Chan KP, Hui DS. et al. Acute exacerbation of COPD. Respirology 2016; 21 (07) 1152-1165
    Search in Google Scholar
  • 6 Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48 (12) 1204-1213 , discussion 1213–1215
    Search in Google Scholar
  • 7 Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29 (06) 1224-1238
    Search in Google Scholar
  • 8 Wedzicha JA, Calverley PMA, Albert RK. et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 50 (03) 1602265
    Search in Google Scholar
  • 9 Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2025 GOLD Report. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2025 Report. 2025 . Accessed October 16, 2025 at: https://goldcopd.org/2025-gold-report/
    Search in Google Scholar
  • 10 Celli BR, Fabbri LM, Aaron SD. et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021; 204 (11) 1251-1258
    Search in Google Scholar
  • 11 Burge S, Wedzicha JA. COPD exacerbations: Definitions and classifications. Eur Respir J Suppl 2003; 41: 46s-53s
    Search in Google Scholar
  • 12 Maeda T, Dransfield MT. COPD and cardiovascular disease: Mechanistic links and implications for practice. Curr Opin Pulm Med 2024; 30 (02) 141-149
    Search in Google Scholar
  • 13 Crisafulli E, Sartori G, Huerta A. et al. Association between Rome Classification among hospitalized patients with COPD exacerbations and short-term and intermediate-term outcomes. Chest 2023; 164 (06) 1422-1433
    Search in Google Scholar
  • 14 Celli BR, Fabbri LM, Aaron SD. et al. Differential diagnosis of suspected chronic obstructive pulmonary disease exacerbations in the acute care setting: Best practice. Am J Respir Crit Care Med 2023; 207 (09) 1134-1144
    Search in Google Scholar
  • 15 Celli BR. Predictors of mortality in COPD. Respir Med 2010; 104 (06) 773-779
    Search in Google Scholar
  • 16 Hurst JR, Vestbo J, Anzueto A. et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363 (12) 1128-1138
    Search in Google Scholar
  • 17 Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): Strengths and limitations. Respir Res 2010; 11 (01) 79
    Search in Google Scholar
  • 18 Spruit MA, Singh SJ, Garvey C. et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188 (08) e13-e64
    Search in Google Scholar
  • 19 Zanini A, Crisafulli E, D'Andria M. et al. Minimum clinically important difference in 30-s sit-to-stand test after pulmonary rehabilitation in subjects with COPD. Respir Care 2019; 64 (10) 1261-1269
    Search in Google Scholar
  • 20 Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56 (11) 880-887
    Search in Google Scholar
  • 21 Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. Effect of a single exacerbation on decline in lung function in COPD. Respir Med 2017; 128: 85-91
    Search in Google Scholar
  • 22 Kerkhof M, Voorham J, Dorinsky P. et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax 2020; 75 (09) 744-753
    Search in Google Scholar
  • 23 Donaldson GC, Law M, Kowlessar B. et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192 (08) 943-950
    Search in Google Scholar
  • 24 Lee HW, Lee JK, Kim Y. et al. Differential decline of lung function in COPD patients according to structural abnormality in chest CT. Heliyon 2024; 10 (07) e27683
    Search in Google Scholar
  • 25 O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164 (05) 770-777
    Search in Google Scholar
  • 26 O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD 2006; 3 (04) 219-232
    Search in Google Scholar
  • 27 Gagnon P, Guenette JA, Langer D. et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 187-201
    Search in Google Scholar
  • 28 Thomas M, Decramer M, O'Donnell DE. No room to breathe: The importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22 (01) 101-111
    Search in Google Scholar
  • 29 Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163 (06) 1395-1399
    Search in Google Scholar
  • 30 Lorenzana I, Galera R, Casitas R. et al. Dynamic hyperinflation is a risk factor for mortality and severe exacerbations in COPD patients. Respir Med 2024; 225: 107597
    Search in Google Scholar
  • 31 Barberà JA, Roca J, Ferrer A. et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997; 10 (06) 1285-1291
    Search in Google Scholar
  • 32 Brill SE, Wedzicha JA. Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 1241-1252
    Search in Google Scholar
  • 33 Wageck B, Cox NS, Holland AE. Recovery following acute exacerbations of chronic obstructive pulmonary disease - A review. COPD 2019; 16 (01) 93-103
    Search in Google Scholar
  • 34 Bräunlich J, Turba K, Wirtz H. Reversibility of hypercapnia after an acute exacerbation of COPD. Respiration 2022; 101 (09) 816-822
    Search in Google Scholar
  • 35 Csoma B, Vulpi MR, Dragonieri S. et al. Hypercapnia in COPD: Causes, consequences, and therapy. J Clin Med 2022; 11 (11) 3180
    Search in Google Scholar
  • 36 Fazekas AS, Aboulghaith M, Kriz RC. et al. Long-term outcomes after acute hypercapnic COPD exacerbation: First-ever episode of non-invasive ventilation. Wien Klin Wochenschr 2018; 130 (19-20): 561-568
    Search in Google Scholar
  • 37 Ahmadi Z, Bornefalk-Hermansson A, Franklin KA, Midgren B, Ekström MP. Hypo- and hypercapnia predict mortality in oxygen-dependent chronic obstructive pulmonary disease: A population-based prospective study. Respir Res 2014; 15 (01) 30
    Search in Google Scholar
  • 38 Vonderbank S, Gibis N, Schulz A. et al. Hypercapnia at hospital admission as a predictor of mortality. Open Access Emerg Med 2020; 12: 173-180
    Search in Google Scholar
  • 39 Rath AK, Sahu D, De S. Oscillometry-defined small airway dysfunction in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul) 2024; 87 (02) 165-175
    Search in Google Scholar
  • 40 Park H, Lee HJ, Lee HW. et al. Diagnosis and evaluation of small airway disease and COPD using impulse oscillometry. Sci Rep 2024; 14 (01) 28030
    Search in Google Scholar
  • 41 Manco A, Pisi R, Aiello M. et al. Small airway dysfunction predicts excess ventilation and dynamic hyperinflation during exercise in patients with COPD. Respir Med X 2020; 2: 100020
    Search in Google Scholar
  • 42 Crisafulli E, Pisi R, Aiello M. et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration 2017; 93 (01) 32-41
    Search in Google Scholar
  • 43 Johnson MK, Birch M, Carter R, Kinsella J, Stevenson RD. Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry. Thorax 2007; 62 (04) 299-306
    Search in Google Scholar
  • 44 Zhang Y, Tanabe N, Shima H. et al. Physiological impairments on respiratory oscillometry and future exacerbations in chronic obstructive pulmonary disease patients without a history of frequent exacerbations. COPD 2022; 19 (01) 149-157
    Search in Google Scholar
  • 45 Lu L, Wu F, Tang G. et al. Associations of small airway dysfunction assessed by impulse oscillometry with lung function decline and exacerbations in participants with chronic obstructive pulmonary disease: A prospective cohort study in China. Respir Med 2025; 241: 108075
    Search in Google Scholar
  • 46 Peng J, Li X, Zhou H, Wang T, Li X, Chen L. Clinical value of impulse oscillometry in chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respiration 2025; 104 (02) 100-109
    Search in Google Scholar
  • 47 Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (05) 1608-1613
    Search in Google Scholar
  • 48 Mannino DM, Clerisme-Beaty EM, Franceschina J, Ting N, Leidy NK. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: Secondary analyses of TICARI 1 trial data. Int J Chron Obstruct Pulmon Dis 2018; 13: 1515-1525
    Search in Google Scholar
  • 49 Perera WR, Hurst JR, Wilkinson TMA. et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29 (03) 527-534
    Search in Google Scholar
  • 50 Similowski T, Suissa S. Systemic steroids in severe forms of COPD exacerbations: A question of balance?. Eur Respir J 2014; 43 (03) 668-670
    Search in Google Scholar
  • 51 Gea J, Pascual S, Casadevall C, Orozco-Levi M, Barreiro E. Muscle dysfunction in chronic obstructive pulmonary disease: Update on causes and biological findings. J Thorac Dis 2015; 7 (10) E418-E438
    Search in Google Scholar
  • 52 Gosker HR, Langen RC, Simons SO. Role of acute exacerbations in skeletal muscle impairment in COPD. Expert Rev Respir Med 2021; 15 (01) 103-115
    Search in Google Scholar
  • 53 Seymour JM, Spruit MA, Hopkinson NS. et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010; 36 (01) 81-88
    Search in Google Scholar
  • 54 Shrikrishna D, Patel M, Tanner RJ. et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012; 40 (05) 1115-1122
    Search in Google Scholar
  • 55 Ansari K, Keaney N, Taylor I, Burns G, Farrow M. Muscle weakness, health status and frequency of exacerbations in chronic obstructive pulmonary disease. Postgrad Med J 2012; 88 (1041) 372-376
    Search in Google Scholar
  • 56 Güerri R, Gayete A, Balcells E. et al. Mass of intercostal muscles associates with risk of multiple exacerbations in COPD. Respir Med 2010; 104 (03) 378-388
    Search in Google Scholar
  • 57 Greening NJ, Harvey-Dunstan TC, Chaplin EJ. et al. Bedside assessment of quadriceps muscle by ultrasound after admission for acute exacerbations of chronic respiratory disease. Am J Respir Crit Care Med 2015; 192 (07) 810-816
    Search in Google Scholar
  • 58 Heubel AD, Kabbach EZ, Leonardi NT. et al. Respiratory and peripheral muscle strength influence recovery of exercise capacity after severe exacerbation of COPD? An observational prospective cohort study. Heart Lung 2023; 58: 91-97
    Search in Google Scholar
  • 59 Jaitovich A, Barreiro E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. What we know and can do for our patients. Am J Respir Crit Care Med 2018; 198 (02) 175-186
    Search in Google Scholar
  • 60 Marchioni A, Castaniere I, Tonelli R. et al. Ultrasound-assessed diaphragmatic impairment is a predictor of outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease undergoing noninvasive ventilation. Crit Care 2018; 22 (01) 109
    Search in Google Scholar
  • 61 Saad M, Pini S, Danzo F. et al. Ultrasonographic assessment of diaphragmatic function and its clinical application in the management of patients with acute respiratory failure. Diagnostics (Basel) 2023; 13 (03) 411
    Search in Google Scholar
  • 62 Zhang T, Liu Y, Wang M. et al. Diaphragm assessment by multimodal ultrasound imaging in patients with chronic obstructive pulmonary disease: A prospective observational study. Int J Chron Obstruct Pulmon Dis 2025; 20: 2629-2638
    Search in Google Scholar
  • 63 Qu L, Zhao W, Zhang W, Li J. Predictive value analysis of diaphragmatic ultrasound evaluation for mechanical ventilation outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med 2025; 25 (01) 478
    Search in Google Scholar
  • 64 Crimi C, Heffler E, Augelletti T. et al. Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients. Int J Chron Obstruct Pulmon Dis 2018; 13: 3131-3139
    Search in Google Scholar
  • 65 Sharma BB, Singh V. Diaphragmatic dysfunction in chronic obstructive pulmonary disease. Lung India 2019; 36 (04) 285-287
    Search in Google Scholar
  • 66 Cao Y, Li P, Wang Y, Liu X, Wu W. Diaphragm dysfunction and rehabilitation strategy in patients with chronic obstructive pulmonary disease. Front Physiol 2022; 13: 872277
    Search in Google Scholar
  • 67 Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23 (01) 28-33
    Search in Google Scholar
  • 68 Aramburu A, Garcia A, Esteban C. et al. Influence of hospitalizations because of COPD exacerbation in the six-minute walk test (6MWT). Eur Respir J 2015; 46 (Suppl. 59) PA410
    Search in Google Scholar
  • 69 Polkey MI, Spruit MA, Edwards LD. et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators. Six-minute-walk test in chronic obstructive pulmonary disease: Minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013; 187 (04) 382-386
    Search in Google Scholar
  • 70 Huang CT, Ruan SY, Lai F, Chien JY, Yu CJ. Prognostic value of pace variability, a novel 6MWT-derived feature, in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2023; 18: 1555-1564
    Search in Google Scholar
  • 71 Prieto-Centurion V, Casaburi R, Coultas DB. et al. Daily physical activity in patients with COPD after hospital discharge in a minority population. Chronic Obstr Pulm Dis (Miami) 2019; 6 (04) 332-340
    Search in Google Scholar
  • 72 Chawla H, Bulathsinghala C, Tejada JP, Wakefield D, ZuWallack R. Physical activity as a predictor of thirty-day hospital readmission after a discharge for a clinical exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11 (08) 1203-1209
    Search in Google Scholar
  • 73 Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest 2006; 129 (03) 536-544
    Search in Google Scholar
  • 74 Watz H, Pitta F, Rochester CL. et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 2014; 44 (06) 1521-1537
    Search in Google Scholar
  • 75 Lindenauer PK, Stefan MS, Pekow PS. et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA 2020; 323 (18) 1813-1823
    Search in Google Scholar
  • 76 Crisafulli E, Torres A, Huerta A. et al. C-reactive protein at discharge, diabetes mellitus and ≥1 hospitalization during previous year predict early readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. COPD 2015; 12 (03) 306-314
    Search in Google Scholar
  • 77 Kersul AL, Iglesias A, Ríos Á. et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011; 47 (04) 176-183
    Search in Google Scholar
  • 78 Ito K, Ito M, Elliott WM. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352 (19) 1967-1976
    Search in Google Scholar
  • 79 Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006; 129 (01) 151-155
    Search in Google Scholar
  • 80 Perng DW, Chen PK. The relationship between airway inflammation and exacerbation in chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul) 2017; 80 (04) 325-335
    Search in Google Scholar
  • 81 Chen H, Luo X, Du Y. et al. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: Data from NHANES 2013-2018. BMC Pulm Med 2023; 23 (01) 318
    Search in Google Scholar
  • 82 Fuhr DP, Brotto AR, Rowe BH, Bhutani M, Rosychuk RJ, Stickland MK. Examining changes in vascular function, arterial stiffness and systemic inflammation during hospitalization and recovery from an acute exacerbation of chronic obstructive pulmonary disease. Sci Rep 2023; 13 (01) 12245
    Search in Google Scholar
  • 83 Xu J, Zeng Q, Li S, Su Q, Fan H. Inflammation mechanism and research progress of COPD. Front Immunol 2024; 15: 1404615
    Search in Google Scholar
  • 84 Ng Kee Kwong F, Nicholson AG, Harrison CL, Hansbro PM, Adcock IM, Chung KF. Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?. Eur Respir Rev 2017; 26 (146) 170040
    Search in Google Scholar
  • 85 Liu YB, Hong JR, Jiang N. et al. The role of mitochondrial quality control in chronic obstructive pulmonary disease. Lab Invest 2024; 104 (02) 100307
    Search in Google Scholar
  • 86 Li CL, Liu JF, Liu SF. Mitochondrial dysfunction in chronic obstructive pulmonary disease: Unraveling the molecular nexus. Biomedicines 2024; 12 (04) 814
    Search in Google Scholar
  • 87 Rabe KF, Rennard S, Martinez FJ. et al. Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: A biologics outlook. Am J Respir Crit Care Med 2023; 208 (04) 395-405
    Search in Google Scholar
  • 88 Beech A, Higham A, Booth S, Tejwani V, Trinkmann F, Singh D. Type 2 inflammation in COPD: Is it just asthma?. Breathe (Sheff) 2024 20. 03
    Search in Google Scholar
  • 89 Polverino F, Sin DD. Type 2 airway inflammation in COPD. Eur Respir J 2024; 63 (05) 2400150
    Search in Google Scholar
  • 90 Christenson SA, Hanania NA, Bhatt SP. et al. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): An analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 2025; 13 (08) 687-697
    Search in Google Scholar
  • 91 Sandelowsky H, Løkke A, Kocks JWH, Grøttum HS, Bakke PS, Vasankari T. The burden of COPD with type 2 inflammation in North-West Continental Europe. Int J Chron Obstruct Pulmon Dis 2025; 20: 2767-2785
    Search in Google Scholar
  • 92 Nordon C, Simons SO, Marshall J. et al. The sustained increase of cardiovascular risk following COPD exacerbations: Meta-analyses of the EXACOS-CV studies. ERJ Open Res 2025; 11 (03) 01091-2024
    Search in Google Scholar
  • 93 Yang HM, Ryu MH, Carey VJ. et al; COPDGene Investigators† . Chronic obstructive pulmonary disease exacerbations increase the risk of subsequent cardiovascular events: A longitudinal analysis of the COPDGene study. J Am Heart Assoc 2024; 13 (11) e033882
    Search in Google Scholar
  • 94 Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32 (04) 962-969
    Search in Google Scholar
  • 95 Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137 (05) 1091-1097
    Search in Google Scholar
  • 96 Rothnie KJ, Connell O, Müllerová H. et al. Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2018; 15 (08) 935-946
    Search in Google Scholar
  • 97 Zysman M, Nordon C, Fabry-Vendrand C. et al. Risk of cardiovascular events according to the severity of an exacerbation of chronic obstructive pulmonary disease. Eur J Prev Cardiol 2025; 32 (15) 1436-1444
    Search in Google Scholar
  • 98 Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107 (11) 1514-1519
    Search in Google Scholar
  • 99 Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B. et al. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir Med 2011; 105 (Suppl. 01) S31-S37
    Search in Google Scholar
  • 100 Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: Common mechanisms and novel therapeutics. Clin Sci (Lond) 2022; 136 (06) 405-423
    Search in Google Scholar
  • 101 Kovacs G, Agusti A, Barberà JA. et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype?. Am J Respir Crit Care Med 2018; 198 (08) 1000-1011
    Search in Google Scholar
  • 102 Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21 (05) 892-905
    Search in Google Scholar
  • 103 Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32 (05) 1371-1385
    Search in Google Scholar
  • 104 Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11 (02) 130-139
    Search in Google Scholar
  • 105 Pirina P, Martinetti M, Spada C. et al; COPD-HF Study Group. Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting. Respir Med 2017; 131: 1-5
    Search in Google Scholar
  • 106 Waeijen-Smit K, Crutsen M, Keene S. et al. Global mortality and readmission rates following COPD exacerbation-related hospitalisation: A meta-analysis of 65 945 individual patients. ERJ Open Res 2024; 10 (01) 00838-02023
    Search in Google Scholar
  • 107 Gunen H, Hacievliyagil SS, Kosar F. et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26 (02) 234-241
    Search in Google Scholar
  • 108 Alqahtani JS, Njoku CM, Bereznicki B. et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: A systematic review and meta-analysis. Eur Respir Rev 2020; 29 (156) 190166
    Search in Google Scholar
  • 109 Papaioannou AI, Hillas G, Loukides S, Vassilakopoulos T. Mortality prevention as the centre of COPD management. ERJ Open Res 2024; 10 (03) 00850-02023
    Search in Google Scholar
  • 110 Li J, Liang L, Samuel Cai Y. et al. Tracking COPD exacerbation patterns and forecasting readmission risks utilizing electronic medical records. Int J Med Inform 2024; 189: 105505
    Search in Google Scholar
  • 111 Ren X, Wang Y, He R. et al. Mortality and readmission risk for hospitalised patients with acute exacerbation of COPD with and without spirometric obstruction: A longitudinal observational study in China. BMJ Open 2023; 13 (06) e071560
    Search in Google Scholar
  • 112 van Hirtum PV, Sprooten RTM, van Noord JA, van Vliet M, de Kruif MD. Long term survival after admission for COPD exacerbation: A comparison with the general population. Respir Med 2018; 137: 77-82
    Search in Google Scholar
  • 113 Boeck L, Soriano JB, Brusse-Keizer M. et al. Prognostic assessment in COPD without lung function: The B-AE-D indices. Eur Respir J 2016; 47 (06) 1635-1644
    Search in Google Scholar
  • 114 Faizal-Gomez CK, Tuta-Quintero E, Lozano-Forero A. et al. Five-year survival and associated factors in COPD patients in Colombia: A retrospective cohort study. Int J Chron Obstruct Pulmon Dis 2025; 20: 3437-3449
    Search in Google Scholar
  • 115 Eroğlu SA, Yakar HI, Yıldız E, Kavas M, Duman D, Günen H. The effect of comorbidities on long-term survival in COPD. Eur Respir J 2018; 52 (Suppl. 62) PA4028
    Search in Google Scholar
  • 116 Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C, Kotanidou A. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med 2009; 24 (09) 1043-1048
    Search in Google Scholar
  • 117 Crisafulli E, Barbeta E, Ielpo A, Torres A. Management of severe acute exacerbations of COPD: An updated narrative review. Multidiscip Respir Med 2018; 13: 36
    Search in Google Scholar
  • 118 Kee YS, Wong CK, Abdul Aziz MA. et al. 30-Day readmission rate of patients with COPD and its associated factors: A retrospective cohort study from a tertiary care hospital. Int J Chron Obstruct Pulmon Dis 2023; 18: 2623-2631
    Search in Google Scholar
  • 119 Caprino R, Sartori G, Sartori F, Fantin A, Crisafulli E. Factors associated with risk of death in hospitalized patients for exacerbation of chronic obstructive pulmonary disease: An updated scoping review. Expert Rev Respir Med 2024; 18 (06) 435-445
    Search in Google Scholar
  • 120 Khamooshi P, Shaka H, Velazquez G, Ovie O, Obiaigwe H, Mohamoud I. Rate and reasons for 30-day readmission following COPD: A United States analysis. Chest 2021; 160 (04) A1899
    Search in Google Scholar
  • 121 Boudreau D, Nebesky JM, Brightling CE, Lebovitch D, Martinez FJ, Samara K. All cause and chronic obstructive pulmonary disease (COPD) specific readmission rates in the U.S. Am J Respir Crit Care Med 2025; 211: A3504
    Search in Google Scholar
  • 122 Hartl S, Lopez-Campos JL, Pozo-Rodriguez F. et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J 2016; 47 (01) 113-121
    Search in Google Scholar
  • 123 Lin P, Shen C, Li Q. et al. A systematic review and meta-analysis of chronic obstructive pulmonary disease in asia: Risk factors for readmission and readmission rate. BMC Pulm Med 2024; 24 (01) 388
    Search in Google Scholar
  • 124 Chow R, So OW, Im JHB. et al. Predictors of readmission, for patients with chronic obstructive pulmonary disease (COPD) - A systematic review. Int J Chron Obstruct Pulmon Dis 2023; 18: 2581-2617
    Search in Google Scholar
  • 125 Ruan H, Zhang H, Wang J, Zhao H, Han W, Li J. Readmission rate for acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Med 2023; 206: 107090
    Search in Google Scholar
  • 126 Shin B, Kim SH, Yong SJ. et al. Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia. Chron Respir Dis 2019; 16: 1479972318809480
    Search in Google Scholar
  • 127 Li J, Ma X, Zeng X, Zhou C, Zhu T. Risk factors of readmission within 90 days for chronic obstructive pulmonary disease patients with frailty and construction of an early warning model. Int J Chron Obstruct Pulmon Dis 2023; 18: 975-984
    Search in Google Scholar
  • 128 Guerrero M, Crisafulli E, Liapikou A. et al. Readmission for acute exacerbation within 30 days of discharge is associated with a subsequent progressive increase in mortality risk in COPD patients: A long-term observational study. PLoS ONE 2016; 11 (03) e0150737
    Search in Google Scholar
  • 129 Early F, Lettis M, Winders SJ, Fuld J. What matters to people with COPD: Outputs from working together for change. NPJ Prim Care Respir Med 2019; 29 (01) 11
    Search in Google Scholar
  • 130 Solomon BK, Wilson KG, Henderson PR, Poulin PA, Kowal J, McKim DA. Loss of dignity in severe chronic obstructive pulmonary disease. J Pain Symptom Manage 2016; 51 (03) 529-537
    Search in Google Scholar
  • 131 De Giorgio A, Dante A, Cavioni V. et al. The IARA model as an integrative approach to promote autonomy in COPD patients through improvement of self-efficacy beliefs and illness perception: A mixed-method pilot study. Front Psychol 2017; 8: 1682
    Search in Google Scholar
  • 132 Van Bakel S, Havermans RC, Schols AMWJ, Gosker HR. Savoring autonomy: Navigating eating barriers in COPD. SSRN Preprint posted online 2024. Doi:
  • 133 Leonardi NT, Kawakami DMO, Cruz J, Burtin C, Borghi-Silva A, Mendes RG. Development of a performance-based toolkit of the treatable traits of functioning in hospitalised patients with exacerbation of COPD: A survey-based study protocol. ERJ Open Res 2024; 10 (02) 00809-02023
    Search in Google Scholar
  • 134 Agusti A, Celli BR, Fabbri L, Vogelmeier C. Managing and discharging COPD patients hospitalized because of an exacerbation of respiratory symptoms: An opportunity to improve outcomes. Eur J Intern Med 2024; 128: 20-22
    Search in Google Scholar
  • 135 Salvi S, Ghorpade D, Nair S. et al. A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: Consensus strategy and expert recommendation. NPJ Prim Care Respir Med 2024; 34 (01) 44
    Search in Google Scholar
  • 136 Rendon A, Luhning S, Bardin P. et al. Recommendations for improving discharge-related care following a COPD exacerbation: An expert panel consensus with emphasis on low- and middle-income countries. Int J Chron Obstruct Pulmon Dis 2025; 20: 1111-1129
    Search in Google Scholar
  • 137 Braido F, Baiardini I, Scichilone N. et al. Disability in moderate chronic obstructive pulmonary disease: Prevalence, burden and assessment - results from a real-life study. Respiration 2015; 89 (02) 100-106
    Search in Google Scholar
  • 138 Horner A, Burghuber OC, Hartl S. et al. Quality of life and limitations in daily life of stable COPD outpatients in a real-world setting in Austria - Results from the CLARA Project. Int J Chron Obstruct Pulmon Dis 2020; 15: 1655-1663
    Search in Google Scholar
  • 139 Leonardi NT, Kawakami DMO, Hurst JR, Cruz J, Mendes RG. Performance-based outcome measures to assess functionality in hospitalised patients with COPD exacerbations: A systematic review of the measurement properties. Eur Respir Rev 2023; 32 (169) 230013
    Search in Google Scholar
  • 140 de Vries MI, Effing TW, van der Palen J, Schrijver J, van der Valk P, Lenferink A. Evaluation of exacerbation and symptom-free time in patients with COPD. COPD 2023; 20 (01) 9-17
    Search in Google Scholar
  • 141 Lenferink A, van der Palen J, van der Valk PDLPM. et al. Exacerbation action plans for patients with COPD and comorbidities: A randomised controlled trial. Eur Respir J 2019; 54 (05) 1802134
    Search in Google Scholar
  • 142 Chai CS, Liam CK, Pang YK. et al. Clinical phenotypes of COPD and health-related quality of life: A cross-sectional study. Int J Chron Obstruct Pulmon Dis 2019; 14: 565-573
    Search in Google Scholar
  • 143 Anandan J, Dwivedi DP, Govindaraj V. Clinical phenotypes of COPD and their impact on quality of life: A cross-sectional study. Respir Med 2023; 220: 107452
    Search in Google Scholar
  • 144 Schwarz SB, Mathes T, Majorski DS. et al. Living conditions and autonomy levels in COPD patients receiving non-invasive ventilation: Impact on health related quality of life. BMC Pulm Med 2021; 21 (01) 255
    Search in Google Scholar
  • 145 Machado A, Dias C, Rebelo P. et al. Functional capacity using sit-to-stand tests in people with chronic obstructive pulmonary disease and its relationship with disease severity-a cross-sectional study with matched controls. Braz J Phys Ther 2024; 28 (04) 101090
    Search in Google Scholar
  • 146 Azhimamatova R, Salieva RS, Zalova TB. et al. Frailty in COPD: Clinical impact, diagnosis, biomarkers, and management strategies. Int J Chron Obstruct Pulmon Dis 2025; 20: 2445-2458
    Search in Google Scholar
  • 147 Cherian M, Masoudian P, Thavorn K, Sandoz J, Shorr R, Mulpuru S. The impact of frailty on clinical outcomes among individuals with COPD: A systematic review and meta-analysis. BMC Pulm Med 2025; 25 (01) 146
    Search in Google Scholar
  • 148 Celli BR, Cote CG, Marin JM. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350 (10) 1005-1012
    Search in Google Scholar
  • 149 Almagro P, Martínez-Camblor P, Miravitlles M. et al; 3CIA Collaboration. External validation and recalculation of the CODEX Index in COPD patients. A 3CIAplus Cohort Study. COPD 2019; 16 (01) 8-17
    Search in Google Scholar
  • 150 Almagro P, Soriano JB, Cabrera FJ. et al; Working Group on COPD, SpanishSociety of Internal Medicine*. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest 2014; 145 (05) 972-980
    Search in Google Scholar
  • 151 Puhan MA, Garcia-Aymerich J, Frey M. et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index. Lancet 2009; 374 (9691) 704-711
    Search in Google Scholar
  • 152 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40 (05) 373-383
    Search in Google Scholar
  • 153 Divo M, Cote C, de Torres JP. et al; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (02) 155-161
    Search in Google Scholar
  • 154 Crisafulli E, Manco A, Torres A. How may we improve clinical outcomes for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease? A narrative review about possible therapeutic and preventive strategies. Expert Rev Respir Med 2020; 14 (05) 493-500
    Search in Google Scholar
  • 155 Di Chiara C, Sartori G, Fantin A, Castaldo N, Crisafulli E. Reducing hospital readmissions in chronic obstructive pulmonary disease patients: Current treatments and preventive strategies. Medicina (Kaunas) 2025; 61 (01) 97
    Search in Google Scholar
  • 156 Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2026 GOLD Report and Pocket Guide. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2026 Report. 2026 . Accessed November 28, 2025 at: https://goldcopd.org/2026-gold-report-and-pocket-guide/
    Search in Google Scholar
  • 157 Romagnoli M, Dell'Orso D, Lorenzi C. et al. Repeated pulmonary rehabilitation in severe and disabled COPD patients. Respiration 2006; 73 (06) 769-776
    Search in Google Scholar
  • 158 Clini EM, Crisafulli E. Exercise capacity as a pulmonary rehabilitation outcome. Respiration 2009; 77 (02) 121-128
    Search in Google Scholar
  • 159 Garrod R, Malerba M, Crisafulli E. Determinants of success. Eur Respir J 2011; 38 (05) 1215-1218
    Search in Google Scholar
  • 160 Jones AV, Evans RA, Harrison AS. et al. Exercise rehabilitation in COPD and heart failure: Comparison of two national audits. ERJ Open Res 2022; 8 (04) 00131-02022
    Search in Google Scholar
  • 161 Crisafulli E, Costi S, De Blasio F. et al. Effects of a walking aid in COPD patients receiving oxygen therapy. Chest 2007; 131 (04) 1068-1074
    Search in Google Scholar
  • 162 Moreau KA, Eady K, Jabbour M. Exploring residents' reactions to and use of parent feedback in a pediatric emergency department: A grounded theory study. Med Teach 2019; 41 (02) 207-214
    Search in Google Scholar
  • 163 Rabe KF, Martinez FJ, Ferguson GT. et al; ETHOS Investigators. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383 (01) 35-48
    Search in Google Scholar
  • 164 Bhatt SP, Wells JM, Kinney GL. et al; COPDGene Investigators. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71 (01) 8-14
    Search in Google Scholar
  • 165 Citgez E, van der Palen J, Koehorst-Ter Huurne K, Movig K, van der Valk P, Brusse-Keizer M. Statins and morbidity and mortality in COPD in the COMIC study: A prospective COPD cohort study. BMJ Open Respir Res 2016; 3 (01) e000142
    Search in Google Scholar
  • 166 Andreas S, Herrmann-Lingen C, Raupach T. et al. Angiotensin II blockers in obstructive pulmonary disease: A randomised controlled trial. Eur Respir J 2006; 27 (05) 972-979
    Search in Google Scholar
  • 167 Vasileiadis IE, Goudis CA, Giannakopoulou PT, Liu T. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers: a promising medication for chronic obstructive pulmonary disease?. COPD 2018; 15 (02) 148-156
    Search in Google Scholar
  • 168 Lai CC, Wang YH, Wang CY, Wang HC, Yu CJ, Chen L. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis 2018; 13: 867-874
    Search in Google Scholar